Need professional-grade analysis? Visit stockanalysis.com
$43.48M
N/A
N/A
N/A
Rallybio Corp (RLYB) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $8.55, up 3.14% from the previous close.
Over the past year, RLYB has traded between a low of $0.64 and a high of $10.97. The stock has gained 259.8% over this period. It is currently 22.1% below its 52-week high.
Rallybio Corp has a market capitalization of $43.48M.
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
Side-by-side comparison against top Healthcare peers.